These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Hsa_circ_0070661 inhibits cancer progression through miR-556-5p/TEK axis in lung adenocarcinoma.
    Author: Chen Y, Wu Y.
    Journal: Cancer Biomark; 2023; 37(1):53-66. PubMed ID: 37005879.
    Abstract:
    BACKGROUND: Lung adenocarcinoma (LUAD) has a high incidence and poor prognosis, and multiple circRNAs (circRNAs) have been found to regulate LUAD. OBJECTIVE: This study focuses on the effect and mechanism of hsa_circ_0070661 in LUAD. METHODS: LUAD tissues and para-cancerous tissues were collected from 38 patients diagnosed with LUAD in our hospital. Hsa_circ_0070661, miR-556-5p and TEK Receptor Tyrosine Kinase (TEK) levels were evaluated using western blotting and RT-qPCR, and the targeting relationship was detected by luciferase reporter and RIP assays. Cell migration, viability, apoptosis-related proteins, (Bcl-2 and Bax) and tumor growth in vivo were assessed by Transwell, CCK-8, western blotting and xenograft assays, respectively. RESULTS: Results indicated downregulation of hsa_circ_0070661 and TEK in LUAD cell lines and tissues, whereas upregulation of miR-556-5p. Hsa_circ_0070661 upregulation restrained the viability, migration and tumor growth of LUAD cells, and promoted apoptosis. Hsa_circ_0070661 could directly target miR-556-5p to upregulate TEK expression in LUAD. MiR-556-5p upregulation promoted the malignant phenotypes of LUAD cells and reversed the anti-cancer effect of hsa_circ_0070661 overexpression, while TEK upregulation inhibited LUAD progression and somewhat eradicated the cancer-promoting effect of miR-556-5p upregulation. CONCLUSIONS: Hsa_circ_0070661 sponges miR-556-5p to inhibit LUAD development via regulating TEK, providing a promising molecular target for LUAD clinical therapy.
    [Abstract] [Full Text] [Related] [New Search]